跳至主要内容
临床试验/NCT03631589
NCT03631589Unknown2 期

Treatment of Steroid-resistant Severe Acute Graft-versus-host Disease With Mesenchymal Stem Cells

Fujian Medical University1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2017年12月1日最近更新:
适应症
干预措施

试验速览

阶段
2 期
发起方
入组人数
50
试验地点
1
主要终点
complete and partial response rate

研究概览

简要总结

Steroid-resistant acute graft-versus-host disease (aGVHD) is one of the most severe complications in the setting of allogeneic hematopoietic stem cell transplantation (HSCT), which cannot be significant benefit from the second-line therapies.The mesenchymal stem cells (MSCs) possess extensive immunomodulatory properties and are very promising to rescue the refractory aGVHD.This study aims to assess the efficacy and safety of MSCs for the treatment of the refractory aGVHD.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed written informed consent
  • Aged <65 years
  • Patients with steroid-resistant severe aGVHD
  • Cardiac: Left ventricular ejection fraction ≥ 50%
  • Adequate renal and hepatic function
  • Performance status: Karnofsky ≥ 70%

排除标准

  • Pregnant or lactating females.
  • Any co-morbidity precluding the administration of MSCs.

研究组 & 干预措施

MSCs treated

Experimental

干预措施: MSCs (Biological)

结局指标

主要结局

complete and partial response rate

时间窗: 1 year

次要结局

  • Adverse events that are related to treatment(1 year)

研究者

发起方
Fujian Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Jianda Hu

Director of the department of Hematology

Fujian Medical University

研究点 (1)

Loading locations...

相似试验